Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Dalpiciclib in Resectable HNSCC
NCT06109207Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of camrelizumab and dalpiciclib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Safety of combination camrelizumab and dalpiciclib at 12 weeks and Feasibility of combination camrelizumab and dalpiciclib at 12 weeks. Started Oct 2023; status: recruiting.
02
Drugs
camrelizumabdalpiciclib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06109207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109207.